Isolation of an Extensively Drug-Resistant Pseudomonas aeruginosa


Journal

Microbiology spectrum
ISSN: 2165-0497
Titre abrégé: Microbiol Spectr
Pays: United States
ID NLM: 101634614

Informations de publication

Date de publication:
26 10 2022
Historique:
pubmed: 11 10 2022
medline: 29 10 2022
entrez: 10 10 2022
Statut: ppublish

Résumé

The aim of this study was to investigate the genomic features of an extensively drug-resistant (XDR) Pseudomonas aeruginosa isolate (P-469) emerging in Chile. Antibiotic susceptibility was determined by disk diffusion and "colistin agar" test. Whole-genome sequencing (WGS) was performed by the Illumina NextSeq 2000 platform, and epidemiologically and clinically relevant data (i.e., sequence-type, serotype, mobile genetic elements, virulome, resistome, plasmidome, prophages, and CRISPR-Cas systems) were retrieved using multiple bioinformatic tools. The P-469 strain displayed an XDR profile, remaining susceptible to colistin. Genomic analysis revealed that this isolate belonged to the "high-risk" clone ST654 (CC654), serotype O4, and genotype

Identifiants

pubmed: 36214677
doi: 10.1128/spectrum.01439-22
pmc: PMC9604125
doi:

Substances chimiques

beta-lactamase NDM-1 EC 3.5.2.6
Colistin Z67X93HJG1
Agar 9002-18-0
Anti-Bacterial Agents 0
beta-Lactamases EC 3.5.2.6

Types de publication

Letter Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0143922

Références

BMC Microbiol. 2022 Jan 6;22(1):13
pubmed: 34991476
Int J Antimicrob Agents. 2020 Dec;56(6):106196
pubmed: 33045347
Braz J Infect Dis. 2019 May - Jun;23(3):203-206
pubmed: 31228460
Clin Microbiol Infect. 2013 Mar;19(3):266-72
pubmed: 22329595
Lancet Infect Dis. 2018 Mar;18(3):318-327
pubmed: 29276051
Sci Rep. 2019 Jul 26;9(1):10874
pubmed: 31350412
Infect Drug Resist. 2020 Oct 22;13:3771-3781
pubmed: 33116695
Front Microbiol. 2021 Feb 18;12:614058
pubmed: 33679638

Auteurs

Andrés Opazo-Capurro (A)

Laboratorio de Antibióticos, Departamento de Microbiología, Facultad de Ciencias Biológicas, Universidad de Concepción, Concepción, Chile.
Millennium Nucleus for Collaborative Research on Bacterial Resistance, Santiago, Chile.

Felipe Morales-León (F)

Laboratorio de Antibióticos, Departamento de Microbiología, Facultad de Ciencias Biológicas, Universidad de Concepción, Concepción, Chile.
Millennium Nucleus for Collaborative Research on Bacterial Resistance, Santiago, Chile.
Departamento de Farmacia, Facultad de Farmacia, Universidad de Concepción, Concepción, Chile.

Christian Jerez (C)

Laboratorio de Antibióticos, Departamento de Microbiología, Facultad de Ciencias Biológicas, Universidad de Concepción, Concepción, Chile.
Department of Restorative School of Dentistry, University of Concepción, Concepción, Chile.

Jorge Olivares-Pacheco (J)

Millennium Nucleus for Collaborative Research on Bacterial Resistance, Santiago, Chile.
Grupo de Resistencia Antibacteriana en Bacterias Patógenas Ambientales GRABPA, Instituto de Biología, Pontificia Universidad Católica de Valparaíso, Valparaíso, Chile.

Manuel Alcalde-Rico (M)

Millennium Nucleus for Collaborative Research on Bacterial Resistance, Santiago, Chile.
Grupo de Resistencia Antibacteriana en Bacterias Patógenas Ambientales GRABPA, Instituto de Biología, Pontificia Universidad Católica de Valparaíso, Valparaíso, Chile.

Paulina González-Muñoz (P)

Laboratorio de Antibióticos, Departamento de Microbiología, Facultad de Ciencias Biológicas, Universidad de Concepción, Concepción, Chile.
Departamento de Ciencias Biológicas y Químicas, Facultad de Medicina y Ciencia, Universidad San Sebastián, Concepción, Chile.

Helia Bello-Toledo (H)

Laboratorio de Antibióticos, Departamento de Microbiología, Facultad de Ciencias Biológicas, Universidad de Concepción, Concepción, Chile.
Millennium Nucleus for Collaborative Research on Bacterial Resistance, Santiago, Chile.

Adriana Cardenas-Arias (A)

Department of Microbiology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil.

Fernanda Esposito (F)

Department of Clinical Analysis, School of Pharmacy, University of São Paulo, São Paulo, Brazil.

Nilton Lincopán (N)

Department of Microbiology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil.
Department of Clinical Analysis, School of Pharmacy, University of São Paulo, São Paulo, Brazil.

Vijna Illesca (V)

Hospital Hernán Henríquez Aravena, Clinical Laboratory, Temuco, Chile.

Gerardo González-Rocha (G)

Laboratorio de Antibióticos, Departamento de Microbiología, Facultad de Ciencias Biológicas, Universidad de Concepción, Concepción, Chile.
Millennium Nucleus for Collaborative Research on Bacterial Resistance, Santiago, Chile.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH